[{"id":"855e0615-efe8-444c-a20c-79fd80778922","acronym":"","url":"https://clinicaltrials.gov/study/NCT07475923","created_at":"2026-03-28T01:38:45.775Z","updated_at":"2026-03-28T01:38:45.775Z","phase":"","brief_title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","source_id_and_acronym":"NCT07475923","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • BRCA","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • HER-2 negative + HR positive + BRCA mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/26/2026","start_date":" 08/26/2026","primary_txt":" Primary completion: 12/31/2031","primary_completion_date":" 12/31/2031","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2026-03-17"},{"id":"7b820269-141f-4024-866b-63f1d5de0853","acronym":"S2206","url":"https://clinicaltrials.gov/study/NCT06058377","created_at":"2023-09-28T14:10:22.699Z","updated_at":"2025-02-25T12:29:51.382Z","phase":"Phase 3","brief_title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","source_id_and_acronym":"NCT06058377 - S2206","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 3680","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-24"},{"id":"cc900cf1-cbd5-4b72-929f-5a7f0c8da6dd","acronym":"KEYNOTE-797","url":"https://clinicaltrials.gov/study/NCT04042701","created_at":"2021-01-18T19:49:50.989Z","updated_at":"2025-02-25T12:37:23.766Z","phase":"Phase 1","brief_title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04042701 - KEYNOTE-797","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 02/10/2020","start_date":" 02/10/2020","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"e34a5a55-d8a1-4469-8532-07c6096c4f21","acronym":"KELLY","url":"https://clinicaltrials.gov/study/NCT03222856","created_at":"2021-01-18T15:54:23.632Z","updated_at":"2025-02-25T14:01:19.405Z","phase":"Phase 2","brief_title":"Ph II Study of Pembrolizumab \u0026 Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines \u0026 Taxanes","source_id_and_acronym":"NCT03222856 - KELLY","lead_sponsor":"MedSIR","biomarkers":" HER-2 • PD-L1 • ER • PGR • TMB","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/14/2017","start_date":" 12/14/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 12/23/2020","study_completion_date":" 12/23/2020","last_update_posted":"2025-02-19"},{"id":"8c941601-ba20-47c7-a04d-a7b15996afd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014658","created_at":"2023-08-28T14:08:42.615Z","updated_at":"2025-02-25T14:18:12.807Z","phase":"Phase 1/2","brief_title":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT06014658","lead_sponsor":"MBrace Therapeutics","biomarkers":" HER-2 • EPHA5","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • EPHA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MBRC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-18"},{"id":"74783677-e3f5-4018-b600-ee9dd649695b","acronym":"ST101-101","url":"https://clinicaltrials.gov/study/NCT04478279","created_at":"2021-01-18T21:30:28.794Z","updated_at":"2025-02-25T14:07:48.179Z","phase":"Phase 1/2","brief_title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04478279 - ST101-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" HR positive • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"de5d05bd-f05a-44a6-8171-14bfffd59db4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03858322","created_at":"2021-01-18T19:02:13.939Z","updated_at":"2025-02-25T14:40:08.507Z","phase":"Phase 1","brief_title":"'ADVANCE' (A Pilot Trial)","source_id_and_acronym":"NCT03858322","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 11/10/2020","primary_completion_date":" 11/10/2020","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-14"},{"id":"e2a7e1c5-e873-49a1-9d76-b61c5d386ab0","acronym":"DESTINY-Breast07","url":"https://clinicaltrials.gov/study/NCT04538742","created_at":"2021-01-18T21:43:10.527Z","updated_at":"2025-02-25T13:53:25.796Z","phase":"Phase 1/2","brief_title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04538742 - DESTINY-Breast07","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-14"},{"id":"d1f68c42-ee96-4408-bbeb-fcdb56335c15","acronym":"SMART-ER","url":"https://clinicaltrials.gov/study/NCT05560685","created_at":"2022-09-29T15:57:06.757Z","updated_at":"2025-02-25T15:13:04.708Z","phase":"","brief_title":"SMART-ER: Symptom Monitoring With Patient-reported Outcomes","source_id_and_acronym":"NCT05560685 - SMART-ER","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 11/03/2025","study_completion_date":" 11/03/2025","last_update_posted":"2025-02-13"},{"id":"d7b81edb-c5fd-48d0-bd93-16279271f44f","acronym":"ICARUS-BREAST01","url":"https://clinicaltrials.gov/study/NCT04965766","created_at":"2021-07-16T13:53:27.986Z","updated_at":"2025-02-25T15:44:32.072Z","phase":"Phase 2","brief_title":"Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT04965766 - ICARUS-BREAST01","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 04/11/2025","primary_completion_date":" 04/11/2025","study_txt":" Completion: 04/11/2028","study_completion_date":" 04/11/2028","last_update_posted":"2025-02-10"},{"id":"876ce078-02f8-4b29-96fc-e46147d9c92f","acronym":"PYX-201-101","url":"https://clinicaltrials.gov/study/NCT05720117","created_at":"2023-09-21T18:11:07.087Z","updated_at":"2025-02-25T16:39:39.072Z","phase":"Phase 1","brief_title":"Study of PYX-201 in Solid Tumors","source_id_and_acronym":"NCT05720117 - PYX-201-101","lead_sponsor":"Pyxis Oncology, Inc","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e micvotabart pelidotin (PYX-201)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-06"},{"id":"c044dc83-7f98-4b8c-81bf-f2a99c8a914c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00769379","created_at":"2021-01-18T02:54:21.132Z","updated_at":"2025-02-25T16:35:59.903Z","phase":"Phase 3","brief_title":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","source_id_and_acronym":"NCT00769379","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2014","initiation":"Initiation: 11/10/2008","start_date":" 11/10/2008","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"e7d7f6f2-3be9-4e74-9f8c-4beb66d4f252","acronym":"AMBITION","url":"https://clinicaltrials.gov/study/NCT04732598","created_at":"2021-02-01T16:58:09.451Z","updated_at":"2025-02-25T16:45:17.111Z","phase":"Phase 3","brief_title":"A Phase III Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer","source_id_and_acronym":"NCT04732598 - AMBITION","lead_sponsor":"Japanese Foundation for Cancer Research","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-05"},{"id":"877e6060-0685-49ad-bf87-696fb090b715","acronym":"","url":"https://clinicaltrials.gov/study/NCT03218826","created_at":"2021-01-18T15:52:53.855Z","updated_at":"2025-02-25T16:51:57.310Z","phase":"Phase 1","brief_title":"PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03218826","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PTEN • PIK3CB","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • PTEN • PIK3CB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • AZD8186"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 07/25/2022","primary_completion_date":" 07/25/2022","study_txt":" Completion: 10/03/2025","study_completion_date":" 10/03/2025","last_update_posted":"2025-02-04"},{"id":"ac946163-6425-4f9a-8c1e-f35619d318be","acronym":"ROSE","url":"https://clinicaltrials.gov/study/NCT05377684","created_at":"2022-05-17T11:53:45.438Z","updated_at":"2025-02-25T17:25:34.281Z","phase":"","brief_title":"Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment","source_id_and_acronym":"NCT05377684 - ROSE","lead_sponsor":"Ipsen","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-01-31"},{"id":"f65dd733-9008-4681-bf13-626c30073cdc","acronym":"SAFIR 03","url":"https://clinicaltrials.gov/study/NCT05625087","created_at":"2022-11-22T15:59:03.927Z","updated_at":"2025-02-25T15:54:42.995Z","phase":"Phase 2","brief_title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","source_id_and_acronym":"NCT05625087 - SAFIR 03","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-01-30"},{"id":"112f7af9-2ce9-46da-a1d8-e2f6494712e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02752685","created_at":"2021-01-17T17:27:16.859Z","updated_at":"2025-02-25T17:35:44.608Z","phase":"Phase 2","brief_title":"Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT02752685","lead_sponsor":"NYU Langone Health","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/29/2022","primary_completion_date":" 12/29/2022","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-29"},{"id":"f03fd2c7-19d1-413f-b17f-ce55b722407c","acronym":"DIRECT","url":"https://clinicaltrials.gov/study/NCT05710328","created_at":"2023-02-02T14:59:59.682Z","updated_at":"2025-02-25T17:38:28.900Z","phase":"Phase 2","brief_title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","source_id_and_acronym":"NCT05710328 - DIRECT","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 235","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 05/31/2027","primary_completion_date":" 05/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-01-29"},{"id":"9bd1e9a9-d299-4cd7-9dec-ff2f9d5e954f","acronym":"PATINA","url":"https://clinicaltrials.gov/study/NCT02947685","created_at":"2021-07-13T22:54:47.342Z","updated_at":"2025-02-25T13:52:11.472Z","phase":"Phase 3","brief_title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","source_id_and_acronym":"NCT02947685 - PATINA","lead_sponsor":"Alliance Foundation Trials, LLC.","biomarkers":" PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive • PIK3CA mutation","tags":["PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • anastrozole • exemestane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 496","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-01-13"},{"id":"de7c1a81-63eb-4f3b-bbdb-13c3636f54e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05203445","created_at":"2022-01-24T17:01:46.426Z","updated_at":"2025-02-25T16:17:12.572Z","phase":"Phase 2","brief_title":"A Study of Olaparib and Pembrolizumab in People with Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer","source_id_and_acronym":"NCT05203445","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D","pipe":" | ","alterations":" HR positive • HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-01-13"},{"id":"fce2d3a2-dfcd-4045-87c5-6fb0389fc58d","acronym":"TBCRC 044","url":"https://clinicaltrials.gov/study/NCT03095352","created_at":"2021-01-18T15:15:08.860Z","updated_at":"2025-02-25T16:05:59.956Z","phase":"Phase 2","brief_title":"Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease","source_id_and_acronym":"NCT03095352 - TBCRC 044","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • carboplatin"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 09/02/2017","start_date":" 09/02/2017","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2025-01-06"},{"id":"f17e9f3e-aca2-40fd-9842-6769913d6623","acronym":"","url":"https://clinicaltrials.gov/study/NCT02520063","created_at":"2021-01-18T12:10:45.080Z","updated_at":"2025-02-25T15:42:33.018Z","phase":"Phase 1/2","brief_title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","source_id_and_acronym":"NCT02520063","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • letrozole • carotuximab IV (ENV-105)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/23/2019","start_date":" 02/23/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-27"},{"id":"970c6f47-72fa-4370-9067-ddab6a5a704f","acronym":"SYNERGY","url":"https://clinicaltrials.gov/study/NCT03616886","created_at":"2021-01-18T17:46:20.617Z","updated_at":"2025-02-25T15:07:48.966Z","phase":"Phase 1/2","brief_title":"Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC","source_id_and_acronym":"NCT03616886 - SYNERGY","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER • PGR • CD73","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • oleclumab (MEDI9447)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-19"}]